68 related articles for article (PubMed ID: 23562634)
1. Novel iontophoretic administration method for local therapy of breast cancer.
Komuro M; Suzuki K; Kanebako M; Kawahara T; Otoi T; Kitazato K; Inagi T; Makino K; Toi M; Terada H
J Control Release; 2013 Jun; 168(3):298-306. PubMed ID: 23562634
[TBL] [Abstract][Full Text] [Related]
2. [Phase I study of TAT-59 (a new antiestrogen) in breast cancer. TAT-59 Study Group].
Nomura Y; Abe O; Enomoto K; Fujiwara K; Tominaga T; Hayashi K; Uchino J; Takahashi M; Hayasaka A; Asaishi K; Okazaki M; Abe R; Kimishima I; Kajiwara T; Haga S; Shimizu T; Miyazaki I; Noguchi M; Yoshida M; Miura S; Taguchi T; Oota J; Sakai K; Kinoshita H; Tashiro H
Gan To Kagaku Ryoho; 1998 Mar; 25(4):553-61. PubMed ID: 9530362
[TBL] [Abstract][Full Text] [Related]
3. [Antitumor activity of miproxifene phosphate (TAT-59) against human mammary carcinoma].
Toko T; Saito H; Fujioka A; Nukatuka M; Sato K; Hashimoto A; Shibata J; Yamada Y
Gan To Kagaku Ryoho; 1998 May; 25(6):829-38. PubMed ID: 9617321
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
[TBL] [Abstract][Full Text] [Related]
5. Ductal access for prevention and therapy of mammary tumors.
Murata S; Kominsky SL; Vali M; Zhang Z; Garrett-Mayer E; Korz D; Huso D; Baker SD; Barber J; Jaffee E; Reilly RT; Sukumar S
Cancer Res; 2006 Jan; 66(2):638-45. PubMed ID: 16423990
[TBL] [Abstract][Full Text] [Related]
6. [Early phase II study of TAT-59 in patients with advanced or recurrent breast cancer--a multicenter dose finding study].
Aoyama H; Tominaga T; Abe O
Gan To Kagaku Ryoho; 1998 May; 25(6):853-65. PubMed ID: 9617324
[TBL] [Abstract][Full Text] [Related]
7. Local transdermal therapy to the breast for breast cancer prevention and DCIS therapy: preclinical and clinical evaluation.
Lee O; Ivancic D; Allu S; Shidfar A; Kenney K; Helenowski I; Sullivan ME; Muzzio M; Scholtens D; Chatterton RT; Bethke KP; Hansen NM; Khan SA
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1235-46. PubMed ID: 26560487
[TBL] [Abstract][Full Text] [Related]
8. [Late phase II study of TAT-59 (miproxifene phospate) in advanced or recurrent breast cancer patients (a double-blind comparative study with tamoxifen citrate)].
Nomura Y; Nakajima M; Tominaga T; Abe O
Gan To Kagaku Ryoho; 1998 Jun; 25(7):1045-63. PubMed ID: 9644320
[TBL] [Abstract][Full Text] [Related]
9. Combination of anti-estrogenic therapy with radiation in breast cancer: simultaneous or sequential treatment?
Schmidberger H; Hermann RM; Hess CF; Emons G
Onkologie; 2005 May; 28(5):275-80. PubMed ID: 15867485
[TBL] [Abstract][Full Text] [Related]
10. Droloxifene, a new antiestrogen, in advanced breast cancer. A double-blind dose-finding study. The Droloxifene 002 International Study Group.
Deschênes L
Am J Clin Oncol; 1991; 14 Suppl 2():S52-5. PubMed ID: 1962599
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of toremifene.
Tominaga T; Abe O; Izuo M; Nomura Y
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S27-9. PubMed ID: 2149281
[TBL] [Abstract][Full Text] [Related]
12. Novel routes for administering chemoprevention: local transdermal therapy to the breasts.
Lee O; Khan SA
Semin Oncol; 2016 Feb; 43(1):107-115. PubMed ID: 26970129
[TBL] [Abstract][Full Text] [Related]
13. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats.
Shin SC; Choi JS; Li X
Int J Pharm; 2006 Apr; 313(1-2):144-9. PubMed ID: 16516418
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.
Iusuf D; Teunissen SF; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2011 Jun; 337(3):710-7. PubMed ID: 21378205
[TBL] [Abstract][Full Text] [Related]
15. [A case of advanced breast cancer successfully treated with combined tamoxifen and epitiostanol].
Konishi Y; Morimoto T; Komaki K; Yamakawa T; Mituyama N; Tanaka T; Oomine Y; Monden Y
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2163-7. PubMed ID: 3395140
[TBL] [Abstract][Full Text] [Related]
16. Orally administered endoxifen is a new therapeutic agent for breast cancer.
Ahmad A; Ali SM; Ahmad MU; Sheikh S; Ahmad I
Breast Cancer Res Treat; 2010 Jul; 122(2):579-84. PubMed ID: 20052538
[TBL] [Abstract][Full Text] [Related]
17. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of droloxifene and its metabolites in breast cancer patients.
Grill HJ; Pollow K
Am J Clin Oncol; 1991; 14 Suppl 2():S21-9. PubMed ID: 1962593
[TBL] [Abstract][Full Text] [Related]
19. Idoxifene: report of a phase I study in patients with metastatic breast cancer.
Coombes RC; Haynes BP; Dowsett M; Quigley M; English J; Judson IR; Griggs LJ; Potter GA; McCague R; Jarman M
Cancer Res; 1995 Mar; 55(5):1070-4. PubMed ID: 7866990
[TBL] [Abstract][Full Text] [Related]
20. [Adjuvant endocrine therapy and chemotherapy of breast cancer (author's transl)].
Heuson JC; Paridaens R
Rev Med Brux; 1982 Apr; 3(4):209-16. PubMed ID: 7046007
[No Abstract] [Full Text] [Related]
[Next] [New Search]
